(Posted by-Desinie Smith)
From the article: "Biogen Idec
(NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced
results from a one-year, longitudinal health outcomes study (n=324) in
which patients with multiple sclerosis (MS) who received 12 infusions of
TYSABRI (natalizumab) reported improvements in quality of life (QoL)
measures, as well as reduced fatigue and overall improved cognitive
function, as measured by validated tools. The goal of the study, which
was performed in conjunction with HealthCore Inc., a health-outcomes
research company, was to assess patient experiences with TYSABRI in a
real-world setting. This research was presented in three posters at the
American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto,
April 10 - 17, 2010. The AAN Annual Meeting is the world's largest
gathering of neurologists."
